Month: July 2020

FORT LAUDERDALE, Fla., July 21, 2020 (GLOBE NEWSWIRE) — via NetworkWire — The Movie Studio, Inc. (OTC: MVES) (the “Company”) proudly announces that it has executed an advertising channel agreement with eStreamTV, a provider of integrating programmatic advertising on television platforms. The agreement will include revenue sharing and integration of eStreamTV into The Movie Studio’s new app, currently available in the Google Play Store and the Apple App Store as part of a soft launch, with full launch anticipated to take place early fall 2020.The initial application of the agreement with eStreamTV will focus on advertiser insertion into The Movie Studio’s OTT and app platform as the “foundation” of the Company’s advertiser video on demand (AVOD) component. Upon completion of the app integration, an initial targeted marketing...

HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.Dear Fellow Shareholders,During this challenging period marked by the ongoing global COVID-19 pandemic, we are continuing to advance our regenerative medicine product candidates with the aim of improving the lives and health of people around the world. In addition to our clinical programs, we are also taking an active role in finding an effective treatment solution to COVID-19 complications. We hope and believe that PLX-PAD may play an instrumental role in overcoming the devastating impact of the coronavirus.  Today I would like to provide...

Philadelphia, PA, July 21, 2020 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) (OTC:VSBGF) (“VSBLTY”), a leading provider of security and retail marketing technology, and Teralight, a global provider of over-the-top (OTT) services to mobile network operators, internet service providers and governments, today jointly announced the signing of a strategic alliance agreement to provide smart city applications enhanced with advanced analytics. Teralight has a strong global customer base in Eastern Europe and the Middle East as well as in Africa and Southeast Asia.The announcement was made by VSBLTY Co-founder & CEO Jay Hutton and Melanie Salvador, Teralight CEO. Hutton said, “Teralight is a special kind of service provider with active relationships in the carrier community. Our products allow carriers...

PRESS RELEASEErgomed H1 2020 Trading UpdateEBITDA for FY 2020 expected to be materially ahead of market expectationsIntegrated pharmaceutical services business demonstrates resilience during Covid-19Total revenue growth of 14.8% over H1 2019; like for like service fee revenue up 18.0% over H1 2019Order book up 22.0% since 1 January 2020 provides high visibility into H2 2020 and beyondStrong cash balance of £14.1 million and debt freeGuildford, UK – 21 July 2020: Ergomed plc, (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, today announces a trading update for the first half of 2020. The Company will provide further details of the first half performance with the publication of its audited interim results in September 2020. Trading materially ahead of expectationsBuilding...

MONTREAL and SARASOTA, Fla., July 21, 2020 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (the “Company”) is pleased to announce that the Toronto Stock Exchange (“TSX”) has approved the renewal of the Company’s normal course issuer bid (“NCIB”). Under the renewed NCIB, the Company will be entitled to repurchase for cancellation up to 4,000,000 common shares, representing 7.13% of the Company’s “public float” as of July 10, 2020, over a twelve-month period starting on July 23, 2020 and ending on July 22, 2021. The purchases by the Company will be effected through the facilities of the TSX and on other alternative trading systems in Canada, and will be made at the market price of the shares at the time of the purchase. There were 59,009,685 common shares of the...

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s Scientific Advisory Board (SAB) with new members. The SAB members serve as strategic advisors to the Company as it continues to advance its pipeline of RNA therapeutics and its proprietary technology platforms.“We are strengthening our Scientific Advisory Board with the addition of leading experts in inherited retinal disease and RNA therapies,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “These individuals bring important scientific, medical, and industry experience, as well as diverse perspectives for us to draw upon. I’m excited...

ROCKVILLE, Md., July 21, 2020 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced the first patient has been enrolled in a proof-of-concept trial evaluating the safety and efficacy of the anti-LIGHT monoclonal antibody, CERC-002, in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome (ARDS).The proof-of-concept, randomized, multicenter, double-blind, placebo-controlled trial will enroll approximately 82 subjects hospitalized with COVID-19 ARDS. The primary objective of the study is to demonstrate that treatment with CERC-002 results in fewer instances of respiratory failure and death versus the standard of care. Patients in the CERC-002 arm...

THE WOODLANDS, Texas, July 21, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these studies will be preserved for upcoming medical congresses and publications.“We are pleased with the evidence of robust A1C reduction and long-term safety in patients with type 2 diabetes demonstrated in these studies,” said Pablo Lapuerta, MD., executive vice president and chief medical officer at Lexicon. “We look forward to presenting and publishing detailed results from these studies in the future.”All four Phase 3 sotagliflozin studies met their primary objectives of lowering A1C in patients with type 2 diabetes.The observed safety profile of sotagliflozin in these studies...